The efficient simultaneous activation of cyclohexenones or simple alkyl acyclic enones and 2‐hydroxynitrostyrenes was realized by using a prolinolthioethercatalyst. Thus, a highly chemo‐, diastereo‐ and enantioselective synthesis of functionalized tetrahydroxanthenones and chromanes with up to three contiguous stereocenters was developed.
Nickel(II)‐Catalyzed Diastereo‐ and Enantioselective Michael/ Hemiacetalization Cascade Reaction of α‐Ketoesters with 2‐(2‐Nitrovinyl)phenols
作者:Long Chen、Wu‐Lin Yang、Jia‐Huan Shen、Wei‐Ping Deng
DOI:10.1002/adsc.201900753
日期:2019.10.8
A nickel(II)/diamine‐catalyzed diastereo‐ and enantioselective Michael/hemiacetalization cascade reaction of α‐ketoesters with 2‐(2‐nitrovinyl)phenols has been established, thus providing a range of structurally diverse polysubstituted chromanes in good yields and excellent stereoselectivities (up to 89% yield, >20:1 dr, >99% ee). Moreover, the gram‐scale experiment was performed with only 0.5 mol%
Formal [4 + 1] cycloaddition strategy for the synthesis of dihydrobenzofurans via Michael addition of 2-(2-nitrovinyl)-phenols and malonate esters (C1 synthon) and subsequent iodine-catalyzed oxidative annulation
作者:Jiaying Leng、Jiang Meng、Xiaoyan Luo、Wei-Ping Deng
DOI:10.1016/j.tet.2018.09.028
日期:2018.12
A novel [4 + 1] cycloaddition protocol for the synthesis of dihydrobenzo(naphtho)furan skeletons from readily available 2-(2-nitrovinyl)-phen(naphth)ols and malonate esters via a tandem Michael addition/iodine-catalyzed oxidative annulation has been developed. This method provides a new and facile application of malonate esters as 1,1-nucleophilic/electrophilic type C1 synthons without a pre-functionalization
MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF
申请人:Akritopoulou-Zanze Irini
公开号:US20110118231A1
公开(公告)日:2011-05-19
The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I)
wherein R
1
, R
2
, R
3
, R
4
, R
5
, A, Y
1
, Y
2
, and Y
3
are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.